GCIOxford Nanopore appoints new CFO
[Lubo Ivanko - stock.adobe.com]
(Sharecast News) - Oxford Nanopore Technologies (ONT) has appointed Nick Keher, a finance veteran in the life sciences sector, as its new chief financial officer, the DNA/RNA sequencing tech firm announced on Monday.
The appointment, effective immediately, will see Tim Cowper move into the chief operating officer (COO), having assumed both roles unofficially for the past five years.
Cowper will now lead the development of the company's expanding international footprint and operations, including operational management of functions like manufacturing, tech transfer, IT, supply chain, global distribution, EHS and set up and management of international facilities.
Keher previously served as CFO of Clinigen Group and Benevolent AI, as well as serving as managing director and head of the European healthcare equity research team at Royal Bank of Canada. Before that he held roles at Investec and GSK after switching from practising pharmacy.
"We are delighted to welcome Nick as CFO," said chief executive Gordon Sanghera. "His experience and expertise of public company financial leadership in an innovative business environment will support our sustainable growth towards profitability. With his scientific background, he also understands the specific opportunities for life science companies. These combine with a passion to deliver impact for all of our stakeholders."
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.